Cargando…
Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. It is characterized by a complex network of physiopathological events where oxidative stress plays a central role among other factors such as neuroinflammation and protein homeostasis. Nuclear factor-erythroid 2 p45-rel...
Autores principales: | Duarte, Pablo, Michalska, Patrycja, Crisman, Enrique, Cuadrado, Antonio, León, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868346/ https://www.ncbi.nlm.nih.gov/pubmed/35204129 http://dx.doi.org/10.3390/antiox11020247 |
Ejemplares similares
-
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
por: Crisman, Enrique, et al.
Publicado: (2022) -
MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011) -
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016) -
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer’s disease
por: Gameiro, Isabel, et al.
Publicado: (2017) -
Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)